(UroToday.com) Prostate cancer is the most common non-cutaneous malignancy among men in the western world, with the vast majority of men having clinically localized disease at the time of diagnosis. For patients with low-risk disease, active surveillance is widely accepted. For patients opting for active treatment, currently accepted treatments including radical prostatectomy and radiotherapy provide good cancer control as evidenced by very high 5-year cancer-specific survival. However, each is associated with significant toxicity. Thus, there has been much ongoing work to identify treatments that provide cancer control with a lower toxicity profile. One such approach is prostate ablation. MRI-guided transurethral ultrasound ablation (TULSA) is a novel minimally-invasive procedure for prostate ablation. In a podium presentation at the American Urologic Association Virtual Annual Meeting, Dr. Eggener and colleagues presented the two-year results of the multicenter TULSA-PRO Ablation Clinical Trial (TACT).